Lawrence Steinman is Director at Pasithea Therapeutics Corp. (KTTA). They have made 5 open-market trades across 3 companies since 2021, most recently 2025-11-28.
CIK 0001132679
5 open-market purchases totalling $297K since 2021, never a sale. Across 5 scored buys the stock is down 12.2% at ninety days, and 14.0 points behind the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| ATNF | 112,493 | $792K |
| BCAB | 78,459 | $140K |
| KTTA | 199,691 | $85K |
| BCEL | 258,405 | $39K |
| Total | $1.1M |
Shares reported on the most recent Form 4, priced at the 2025-12-01 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 40% | 40% | 40% |
| Avg Move | +5.0% | -1.4% | -12.2% |
| Alpha | +4.0% | -2.6% | -14.0% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| KTTA | BUY | 2025-11-28 | 2025-12-01 | $0.75 | $200K | -2.6% | +12.2% | -29.2% |
| BCAB | BUY | 2023-12-19 | 2023-12-19 | $2.05 | $41K | +26.2% | -1.0% | +11.4% |
| KTTA | BUY | 2023-06-02 | 2023-06-06 | $0.43 | $13K | -0.1% | +6.3% | +26.6% |
| ATNF | BUY | 2023-06-01 | 2023-06-02 | $1.23 | $22K | -1.7% | -6.7% | -44.0% |
| ATNF | BUY | 2021-12-09 | 2021-12-10 | $4.27 | $21K | +3.0% | -17.7% | -25.6% |
| BCAB | SELL · 10b5-1 | 2021-11-02 | 2021-11-03 | $30.00 | $14K | -12.2% | -27.3% | -69.3% |
| BCAB | SELL · 10b5-1 | 2021-09-15 | 2021-09-17 | $36.82 | $17K | -9.6% | -19.1% | -42.9% |
| BCAB | SELL · 10b5-1 | 2021-08-16 | 2021-08-18 | $40.60 | $18K | +0.8% | -14.0% | -30.7% |
| BCAB | SELL · 10b5-1 | 2021-07-15 | 2021-07-19 | $38.29 | $17K | +1.3% | +2.0% | -30.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.